Datopotamab deruxtecan
Datroway (datopotamab deruxtecan) is an antibody drug conjugate pharmaceutical. Datopotamab deruxtecan was first approved as Datroway on 2025-01-17.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Datroway
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Datopotamab deruxtecan
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Datroway | datopotamab deruxtecan-dlnk | Daiichi Pharmaceutical | N-761394 RX | 2025-01-17 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| datroway | Biologic Licensing Application | 2025-07-10 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 4 | 5 | 7 | — | 1 | 16 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 3 | 6 | — | — | 10 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 3 | 1 | — | 1 | 5 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | 4 | — | — | 5 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | 1 | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | — | — | 1 | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | 1 | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | — | 2 | 2 | — | — | — | 3 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 2 | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | — | 1 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 1 | — | — | — | 1 |
| Male breast neoplasms | D018567 | — | — | — | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Datopotamab deruxtecan |
| INN | datopotamab deruxtecan |
| Description | Ds-1062 is an unknown pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Unknown |
| Drug class | monoclonal antibodies; antineoplastics (camptothecin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297939 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB16410 |
| UNII ID | GD2OWY1DTK (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
115 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use